The effects of probiotic on clinical findings in patients with allergic rhinitis and asthma

The present study aims to investigate the role of probiotics as one of the treatments for preventing allergic rhinitis and asthma, along with routine therapies, in order to reduce the burden of diseases.

In this double-blinded randomized clinical trial, 30 patients will be studied through 2 groups of 15 participants. The intervention group will be under the treatment of Familact probiotic (Zist Takhmir, Iran) together with the previous common medication. The control group will receive only previous routine medications.

The study is conducted at Tabriz Imam Reza Hospital. According to the checklist, the study variables of the patients before treatment and after treatment will be analyzed. Patients randomly entering into two groups, probiotic and placebo are delivered to people for eight weeks.

Inclusion criteria: All people over the age of 15, including the male and the female, who have allergic rhinitis. All people over the age of 15, including male and females, who have asthma. Non inclusion criteria: Using antibiotics in the past 4 weeks; Food allergy; Lactose intolerance; suffering from chronic diseases; Use of corticosteroids; Suffering from underlying diseases other than asthma; Suffering from other kinds of rhinitis and respiratory diseases

Intervention group: Individuals with allergic rhinitis and asthma who receive a probiotic supplement for 8 weeks in addition to their previous routine treatment. Control group: People with allergic rhinitis and asthma who receive a placebo for 8 weeks in addition to previous routine therapy.

Cough, post nasal drip, nasal discharge, nasal polyps, sleep disturbances, dyspnea, snoring, turbinates hypertrophy and quality of life

Approved funds of Tabriz University of Medical Sciences

After the primary visit, the participants who meet the inclusion criteria will be allocated by randomization software into two groups. The random allocation will be done through blocks of size 8 in order to make balance in number between male and female.

After signing informed consent by all participants, the participants will be numbered by a tertiary investigator and the numbers will be entered to the randomization software. After allocating the participants to the two groups by randomization software, the case and control groups will be determined. Then the supplements and placebo will be given to the secondary investigator, who is blind to the sequence of entering to the study. Finally, the supplements and placebo will be given to the patients of each group which is determined by the tertiary investigator who is not aware of the content of the capsules.

No more information

Only a portion of the data, such as its original information, can be shared.

Start the access period 6 months after printing the results

Data will only be available to researchers working in academic and scientific institutions .

All academic and researcher / all statistical analyzes are unhelpful . Use of data with the permission of the researcher and the maintenance of relevant rights .

Visit the Vice-Chancellor of Research and Technology of Tabriz University of Medical Sciences or contact the researcher . Phone number: 989143821138+ or home phone: 00984133339589

Access to the data is possible after two weeks after submitting to the relevant units and requesting a maximum of two weeks